Skip to main content
. 2022 Aug 3;11(15):4518. doi: 10.3390/jcm11154518

Table 2.

Statistical significance (p-value) of the effect of each variable in longitudinal remission and durability.

Longitudinal Remission Durability
Feature Non-Discretized Discretized *
Days since start of UST treatment <0.05 <0.05 <0.05
HBI at the first UST dose, categorized <0.05 <0.05 0.083
Years between diagnosis and start of UST <0.05 0.547 0.077
Number of surgeries before UST treatment onset <0.05 <0.05 0.24
Number of anti-TNF episodes <0.05 0.09 <0.05
Number of anti-integrin episodes <0.05 <0.05 <0.05
Age at the time of signing consent <0.05 <0.05 <0.05
BMI at baseline <0.05 <0.05 <0.05
Sex 0.888 N/A 0.842
Number of comorbidities <0.05 <0.05 0.296
Perianal disease <0.05 <0.05 0.541
Location of CD <0.05 <0.05 0.137
Patient ever had EIMs 0.806 N/A 0.648
Family history of CD 0.958 N/A 0.998
Upper gastrointestinal tract (L4) involved 0.999 N/A 0.828
Baseline albumin <0.05 0.431 0.357
Baseline fecal calprotectin <0.05 0.26 <0.05
Baseline hemoglobin <0.05 0.77 <0.05
Baseline CRP <0.05 <0.05 <0.05
Under Steroids at first UST dose <0.05 <0.05 0.237
Under Immunosuppressants at first UST dose <0.05 <0.05 0.813
Number of concomitant Steroid courses <0.05 <0.05 <0.05

Variables that were significant in longitudinal remission (non-discretized) and durability models are indicated in bold. * All features discretized, except for “days since start of UST treatment”. BMI, Body Mass Index; CD, Crohn’s Disease; CRP, C-reactive protein; EIM, extraintestinal manifestation; HBI, Harvey Bradshaw Index; TNF, Tumor Necrosis Factor; UST, ustekinumab.